Rights and permissions
About this article
Cite this article
Re-approval of Vioxx requires additional US FDA committee consideration. React. Wkly. 1050, 3 (2005). https://doi.org/10.2165/00128415-200510500-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-200510500-00007